BKM120 sensitizes glioblastoma to the PARP inhibitor rucaparib by suppressing homologous recombination repair

AbstractPARP inhibitors have been approved for the therapy of cancers with homologous recombination (HR) deficiency based on the concept of “synthetic lethality”. However, glioblastoma (GBM) patients have gained little benefit from PARP inhibitors due to a lack of BRCA mutations. Herein, we demonstrated that concurrent treatment with the PARP inhibitor rucaparib and the PI3K inhibitor BKM120 showed synergetic anticancer effects on GBM U251 and U87MG cells. Mechanistically, BKM120 decreased expression of HR molecules, including RAD51 and BRCA1/2, and reduced HR repair efficiency in GBM cells, therefore increasing levels of apoptosis induced by rucaparib. Furthermore, we discovered that the two compounds complemented each other in DNA damage response and drug accumulation. Notably, in the zebrafish U87MG-RFP orthotopic xenograft model, nude mouse U87MG subcutaneous xenograft model and U87MG-Luc orthotopic xenograft model, combination showed obviously increased antitumor efficacy compared to each monotherapy. Immunohistochemical analysis of tumor tissues indicated that the combination obviously reduced expression of HR repair molecules and increased the DNA damage biomarker γ-H2AX, consistent with the in vitro results. Collectively, our findings provide new insight into combined blockade of PI3K and PARP, which might represent a promising therapeutic approach for GBM.

Topics

No keywords indexed for this article. Browse by subject →

References

46

[1]

Reitman, Z. J., Winkler, F. & Elia, A. E. H. New directions in the treatment of glioblastoma. Semin Neurol. 38, 50–61 (2018). 10.1055/s-0038-1623534

[2]

Murai, J. et al. Rationale for poly(ADP-ribose) polymerase (PARP) inhibitors in combination therapy with camptothecins or temozolomide based on PARP trapping versus catalytic inhibition. J. Pharm. Exp. Ther. 349, 408–416 (2014). 10.1124/jpet.113.210146

[3]

Vengoji, R. et al. Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells. J. Exp. Clin. Cancer Res. 38, 266 (2019). 10.1186/s13046-019-1264-2

[4]

Senra, J. M. et al. Inhibition of PARP-1 by olaparib (AZD2281) increases the radiosensitivity of a lung tumor xenograft. Mol. Cancer Ther. 10, 1949–1958 (2011). 10.1158/1535-7163.mct-11-0278

[5]

Ashworth, C. J. L. A. PARP inhibitors: Synthetic lethality in the clinic. Science 335, 1152–1158 (2017).

[6]

Vyas, S. et al. Family-wide analysis of poly(ADP-ribose) polymerase activity. Nat. Commun. 5, 4426 (2014). 10.1038/ncomms5426

[7]

Pai Bellare, G., Saha, B. & Patro, B. Targeting autophagy reverses de novo resistance in homologous recombination repair proficient breast cancers to PARP inhibition. Br. J. Cancer 124, 1260–1274 (2021). 10.1038/s41416-020-01238-0

[8]

Coyne, G. O. S., Chen, A. P., Meehan, R. & Doroshow, J. H. PARP inhibitors in reproductive system cancers: current use and developments. Drugs 77, 113–130 (2017). 10.1007/s40265-016-0688-7

[9]

Barazzuol, L. et al. Evaluation of poly (ADP-ribose) polymerase inhibitor ABT-888 combined with radiotherapy and temozolomide in glioblastoma. Radiat. Oncol. 8, 1–11 (2013). 10.1186/1748-717x-8-65

[10]

Gonzalez-Billalabeitia, E. et al. Vulnerabilities of PTEN-TP53-deficient prostate cancers to compound PARP-PI3K inhibition. Cancer Disco. 4, 896–904 (2014). 10.1158/2159-8290.cd-13-0230

[11]

An Integrated Genomic Analysis of Human Glioblastoma Multiforme

D. Williams Parsons, Siân Jones, Xiaosong Zhang et al.

Science 2008 10.1126/science.1164382

[12]

Atkins, R. J., Ng, W., Stylli, S. S., Hovens, C. M. & Kaye, A. H. Repair mechanisms help glioblastoma resist treatment. J. Clin. Neurosci. 22, 14–20 (2015). 10.1016/j.jocn.2014.09.003

[13]

Konstantinopoulos, P. A. et al. Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial. Lancet Oncol. 20, 570–580 (2019). 10.1016/s1470-2045(18)30905-7

[14]

Chou, T. C. & Talalay, P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzym. Regul 22, 27–55 (1984). 10.1016/0065-2571(84)90007-4

[15]

Pilie, P. G., Tang, C., Mills, G. B. & Yap, T. A. State-of-the-art strategies for targeting the DNA damage response in cancer. Nat. Rev. Clin. Oncol. 16, 81–104 (2019). 10.1038/s41571-018-0114-z

[16]

Carlsson, S. K., Brothers, S. P. & Wahlestedt, C. Emerging treatment strategies for glioblastoma multiforme. EMBO Mol. Med. 6, 1359–1370 (2014). 10.15252/emmm.201302627

[17]

Rasmussen, R. D. et al. BRCA1-regulated RRM2 expression protects glioblastoma cells from endogenous replication stress and promotes tumorigenicity. Nat. Commun. 7, 13398 (2016). 10.1038/ncomms13398

[18]

Netland, I. A. et al. Treatment with the PI3K inhibitor buparlisib (NVP-BKM120) suppresses the growth of established patient-derived GBM xenografts and prolongs survival in nude rats. J. Neurooncol 129, 57–66 (2016). 10.1007/s11060-016-2158-1

[19]

Wang, D. et al. Effective use of PI3K inhibitor BKM120 and PARP inhibitor Olaparib to treat PIK3CA mutant ovarian cancer. Oncotarget 7, 13153–13166 (2015). 10.18632/oncotarget.7549

[20]

Matulonis, U. A. et al. Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancer. Ann. Oncol. 28, 512–518 (2017). 10.1093/annonc/mdw672

[21]

Ibrahim, Y. H. et al. PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition. Cancer Disco. 2, 1036–1047 (2012). 10.1158/2159-8290.cd-11-0348

[22]

Juvekar, A. et al. Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer. Cancer Disco. 2, 1048–1063 (2012). 10.1158/2159-8290.cd-11-0336

[23]

Li, L. et al. Androgen receptor inhibitor-induced “BRCAness” and PARP inhibition are synthetically lethal for castration-resistant prostate cancer. Sci. Signal 10, eaam7479 (2017). 10.1126/scisignal.aam7479

[24]

Yang, L. et al. Combined treatment with PI3K inhibitor BKM120 and PARP inhibitor olaparib is effective in inhibiting the gastric cancer cells with ARID1A deficiency. Oncol. Rep. 40, 479–487 (2018).

[25]

Erasimus, H., Gobin, M., Niclou, S. & Van Dyck, E. DNA repair mechanisms and their clinical impact in glioblastoma. Mutat. Res Rev. Mutat. Res. 769, 19–35 (2016). 10.1016/j.mrrev.2016.05.005

[26]

Ko, J. C. et al. Astaxanthin down-regulates Rad51 expression via inactivation of AKT kinase to enhance mitomycin C-induced cytotoxicity in human non-small cell lung cancer cells. Biochem. Pharm. 105, 91–100 (2016). 10.1016/j.bcp.2016.02.016

[27]

Boichuk, S. et al. Inhibition of AKT-signaling sensitizes soft tissue sarcomas (STS) and gastrointestinal stromal tumors (GIST) to doxorubicin via targeting of homology-mediated DNA repair. Int J. Mol. Sci. 21, 8842 (2021). 10.3390/ijms21228842

[28]

Yazinski, S. A. et al. ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells. Genes Dev. 31, 318–332 (2017). 10.1101/gad.290957.116

[29]

Kumar, A., Fernandez-Capetillo, O. & Carrera, A. C. Nuclear phosphoinositide 3-kinase beta controls double-strand break DNA repair. Proc. Natl Acad. Sci. USA 107, 11145 (2010). 10.1073/pnas.0914242107

[30]

Andrabi, S. A. et al. Poly(ADP-ribose) polymerase-dependent energy depletion occurs through inhibition of glycolysis. Proc. Natl Acad. Sci. USA 111, 10209–10214 (2014). 10.1073/pnas.1405158111

[31]

Galia, A. et al. PARP-1 protein expression in glioblastoma multiforme. Eur. J. Histochem. 56, e9 (2012). 10.4081/ejh.2012.e9

[32]

Stylli, S. S., Luwor, R. B., Ware, T. M., Tan, F. & Kaye, A. H. Mouse models of glioma. J. Clin. Neurosci. 22, 619–626 (2015). 10.1016/j.jocn.2014.10.013

[33]

Vargas-Patron, L. A. et al. Xenotransplantation of human glioblastoma in Zebrafish larvae: in vivo imaging and proliferation assessment. Biol. Open 8, bio.043257 (2019). 10.1242/bio.043257

[34]

Gomez-Zepeda, D., Taghi, M., Scherrmann, J. M., Decleves, X. & Menet, M. C. ABC transporters at the blood-brain interfaces, their study models, and drug delivery implications in gliomas. Pharmaceutics 12, 20 (2019). 10.3390/pharmaceutics12010020

[35]

Parrish, K. E. et al. Efficacy of PARP inhibitor rucaparib in orthotopic glioblastoma xenografts is limited by ineffective drug penetration into the central nervous system. Mol. Cancer Ther. 14, 2735–2743 (2015). 10.1158/1535-7163.mct-15-0553

[36]

Zhang, L. et al. The PI3K subunits, P110alpha and P110beta are potential targets for overcoming P-gp and BCRP-mediated MDR in cancer. Mol. Cancer 19, 10 (2020). 10.1186/s12943-019-1112-1

[37]

Oberoi, R. K. et al. Strategies to improve delivery of anticancer drugs across the blood-brain barrier to treat glioblastoma. Neuro Oncol. 18, 27–36 (2016). 10.1093/neuonc/nov164

[38]

Wang, Y. et al. ZSTK474, a specific class I phosphatidylinositol 3-kinase inhibitor, induces G1 arrest and autophagy in human breast cancer MCF-7 cells. Oncotarget 7, 19897–19909 (2015). 10.18632/oncotarget.7658

[39]

Zhou, Q. et al. Antiproliferative effect of ZSTK474 alone or in combination with chemotherapeutic drugs on HL60 and HL60/ADR cells. Oncotarget 8, 39064–39076 (2017). 10.18632/oncotarget.16589

[40]

Wang, R. et al. Stellettin B Induces G1 arrest, apoptosis and autophagy in human non-small cell lung cancer A549 cells via blocking PI3K/Akt/mTOR pathway. Sci. Rep. 6, 27071 (2016). 10.1038/srep27071

[41]

Wang, Z. et al. DT-13 inhibits proliferation and metastasis of human prostate cancer cells through blocking PI3K/Akt pathway. Front Pharm. 9, 1450 (2018). 10.3389/fphar.2018.01450

[42]

Wang, Y. et al. Digoxin enhances the anticancer effect on non-small cell lung cancer while reducing the cardiotoxicity of adriamycin. Front Pharm. 11, 186 (2020). 10.3389/fphar.2020.00186

[43]

Zhang, L. et al. Atorvastatin exerts antileukemia activity via inhibiting mevalonate-YAP Axis in K562 and HL60 Cells. Front Oncol. 9, 1032 (2019). 10.3389/fonc.2019.01032

[44]

Mo, W. et al. mTOR inhibitors suppress homologous recombination repair and synergize with PARP inhibitors via regulating SUV39H1 in BRCA-proficient triple-negative breast cancer. Clin. Cancer Res. 22, 1699–1712 (2016). 10.1158/1078-0432.ccr-15-1772

[45]

Peng, X. et al. Co-targeting PI3K/Akt and MAPK/ERK pathways leads to an enhanced antitumor effect on human hypopharyngeal squamous cell carcinoma. J. Cancer Res Clin. Oncol. 145, 2921–2936 (2019). 10.1007/s00432-019-03047-2

[46]

Zhang, Z. et al. Biomimetic carrier-free nanoparticle delivers digoxin and doxorubicin to exhibit synergetic antitumor activity in vitro and in vivo. Chem. Eng. J. 406, 126801 (2021). 10.1016/j.cej.2020.126801

Cited By

42

Post-translational modifications in DNA damage repair: mechanisms underlying temozolomide resistance in glioblastoma

Yike Chen, Kaikai Ding · 2025

Oncogene

Regulated cell death (RCD) in cancer: key pathways and targeted therapies

Fu Peng, Minru Liao · 2022

Signal Transduction and Targeted Th...

Metrics

42

Citations

46

References

Details

Published: May 26, 2021
Vol/Issue: 12(6)
License: View

Authors

Department of Psychology, Zhejiang Sci-Tech University

Hong Kong University of Science and Technology

R

Ran Wang

MOE Key Laboratory of Macromolecular Synthesis and Functionalization Key Laboratory of Adsorption and Separation Materials & Technologies of Zhejiang Province Department of Polymer Science and Engineering Zhejiang University 38 Zheda Road Hangzhou 310027 P. R. China

Funding

National Natural Science Foundation of China Award: 81673464

Major Project of Tianjin for New Drug Development

Cite This Article

Shaolu Zhang, Xin Peng, Xiaofei Li, et al. (2021). BKM120 sensitizes glioblastoma to the PARP inhibitor rucaparib by suppressing homologous recombination repair. Cell Death & Disease, 12(6). https://doi.org/10.1038/s41419-021-03805-6

BKM120 sensitizes glioblastoma to the PARP inhibitor rucaparib by suppressing homologous recombination repair

You May Also Like